Allergologie select最新文献_第5页

Individual wearable air purifier protects against pollen, house dust mite, and cat allergens: Report from an allergen exposure chamber. 个人可穿戴式空气净化器可防止花粉、屋尘螨和猫的过敏原：过敏原暴露室的报告

Allergologie select Pub Date : 2024-03-21 eCollection Date: 2024-01-01 DOI: 10.5414/ALX02473E

Karl-Christian Bergmann, Teresa Hartung, Torsten Zuberbier

{"title":"Individual wearable air purifier protects against pollen, house dust mite, and cat allergens: Report from an allergen exposure chamber.","authors":"Karl-Christian Bergmann, Teresa Hartung, Torsten Zuberbier","doi":"10.5414/ALX02473E","DOIUrl":"10.5414/ALX02473E","url":null,"abstract":"Purpose: Evaluation of a new individual wearable air purifier (Respiray Wear A+) for birch pollen, house dust mite (HDM), and cat-allergic rhinoconjunctivitis (ARC) patients in a standardized allergen exposure chamber (AEC).Materials and methods: Eligible allergic patients were exposed to birch pollen, HDM raw material, and cat allergen in an AEC for 60 minutes without (V1) and with (V3) the use of the Respiray device. Nasal, ocular, bronchial, and other symptoms were rated by the patients every 10 minutes, and their wellbeing, peak nasal inspiratory flow (PNIF), and lung function parameters were assessed every 30 minutes. The primary endpoint was the change in the median of the total symptom score (TSS) at V3 compared to V1 at 60 minutes of exposure. The secondary endpoints consisted of the total nasal symptom score (TNSS) and total eye symptom score (TESS).Results: 23 patients with birch pollen allergy, 37 patients with HDM allergy, and 41 patients with cat allergy were included in the analysis. Significant reduced symptom scores of ~ 49% were observed when using Respiray Wea A+ under birch pollen exposure (p < 0.05) in the primary endpoint TSS (V3 2.43 compared to V1 4.78). An 48% reduction of symptoms was seen in TSS in case of HDM exposure (V3 3.59; V1 6.92, (t-test: p < 0.01)) and the highest reduction of TSS (60%) under Respiray A+ using cat allergens (V3 2.95, V1 7.44, (t-test p < 0.01) after 60 minutes of exposure. The personal wellbeing revealed clinically meaningful improvements over time in all three studies which manifested in a lower symptom increase during the final allergen exposures.Conclusion: The individual wearable air purifier Respiray Wear A+ protects significantly against airborne pollen, HDM, and cat allergens and may be a very useful device for avoiding indoor allergens in a new way.","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"70-77"},"PeriodicalIF":0.0,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10975740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypoallergenic animals: A promise of hope for allergic patients? 低过敏性动物：过敏症患者的希望？

Allergologie select Pub Date : 2024-03-21 eCollection Date: 2024-01-01 DOI: 10.5414/ALX02454E

Christiane Hilger, Bente Janssen-Weets, Kyra Swiontek

引用次数: 0

Role of FEF25-75 in characterizing outpatients with asthma in clinical practice. FEF25-75 在临床实践中描述门诊哮喘患者特征的作用。

Allergologie select Pub Date : 2024-01-12 eCollection Date: 2024-01-01 DOI: 10.5414/ALX02453E

Giorgio Ciprandi, Irene Schiavetti

{"title":"Role of FEF25-75 in characterizing outpatients with asthma in clinical practice.","authors":"Giorgio Ciprandi, Irene Schiavetti","doi":"10.5414/ALX02453E","DOIUrl":"10.5414/ALX02453E","url":null,"abstract":"Background: Asthma is characterized by variable airflow limitation. FEF25-75 has been proposed as a reliable marker for bronchial obstruction, especially when FEV1 and FEV1/FVC are normal.Objectives: To investigate the role of FEF25-75 in patients with asthma seen in clinical settings.Materials and methods: The cross-sectional study included 439 (181 females and 255 males; mean age 39 years) outpatients with asthma who consecutively visited an allergy clinic for a routine assessment. History, physical examination, asthma control, and spirometry were evaluated.Results: FEF25-75 was impaired (< 65% of predicted) in 136 (31%) outpatients. Considering only subjects with normal FEV1 and FEV1/FVC, FEF25-75 was impaired in 71 (19.6%) subjects. In this subset, impaired FEF25-75 was associated with low FEV1 and FEV1/FVC values (OR 0.91 and 0.85, respectively), and presence of asthma symptoms (OR 2.19).Conclusion: FEF25-75 deserves adequate and careful consideration in patients with asthma and normal FEV1 and FEV1/FVC, as the presence of impaired FEF25-75 in this subset suggests a more specific approach.","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"12-17"},"PeriodicalIF":0.0,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allergen immunotherapy for allergic asthma. 过敏性哮喘的过敏原免疫疗法。

Allergologie select Pub Date : 2024-01-12 eCollection Date: 2024-01-01 DOI: 10.5414/ALX02451E

J Christian Virchow, Oliver Pfaar, Marek Lommatzsch

引用次数: 0

Asthma therapy concepts through the ages. 历代哮喘治疗理念

Allergologie select Pub Date : 2024-01-12 eCollection Date: 2024-01-01 DOI: 10.5414/ALX02445E

Marek Lommatzsch

{"title":"Asthma therapy concepts through the ages.","authors":"Marek Lommatzsch","doi":"10.5414/ALX02445E","DOIUrl":"10.5414/ALX02445E","url":null,"abstract":"The development and approval of DMAADs (\"disease-modifying anti-asthmatic drugs\"), in particular inhaled steroids (alone or in combination with long-acting bronchodilators), biologics and modern allergen immunotherapies, has fundamentally changed the asthma therapy concept from symptom control to symptom prevention. This concept is linked to the new asthma treatment goal of asthma remission: long-term absence of symptoms (good asthma control), absence of exacerbations, and stable lung function, without the use of systemic steroids for asthma therapy. Three types of asthma remission are distinguished: spontaneous remission (e.g., childhood asthma), remission \"off treatment\" (e.g., after successful allergen immunotherapy), and remission \"on treatment\" (e.g., during inhaled therapy or biologic therapy). A treat-to-target approach is used, as in rheumatoid arthritis or chronic inflammatory bowel disease: The goal is to achieve asthma remission, through individually tailored treatment with highly effective drugs with minimal side effects. However, this requires precise phenotyping of the patient, including detailed history taking, pulmonary function diagnostics, allergological diagnostics, and measurement of type 2 biomarkers.","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AIT in pediatric allergology: Opportunities and difficulties on the home stretch of the Therapy Allergen Ordinance. 儿科过敏学中的 AIT：治疗过敏原条例》的机遇与困难并存。

Allergologie select Pub Date : 2023-12-12 eCollection Date: 2023-01-01 DOI: 10.5414/ALX02443E

Christian Vogelberg, Michael Gerstlauer

{"title":"AIT in pediatric allergology: Opportunities and difficulties on the home stretch of the Therapy Allergen Ordinance.","authors":"Christian Vogelberg, Michael Gerstlauer","doi":"10.5414/ALX02443E","DOIUrl":"https://doi.org/10.5414/ALX02443E","url":null,"abstract":"Allergen immunotherapy (AIT) is the only causal therapy for allergic diseases and therefore particularly important. Allergen preparations have been classified as medicinal products since 1989 (Directive 89/342/EEC) and were taken over into Directive 2001/83/EC in 2001. In addition, in 2008 the Therapy Allergen Ordinance (TAO) came into force to stricter regulate the exception for named patient products (NPP) by exclusion of common therapy allergens from the exception to be marketed as NPP. The TAO regulates the requirements for testing safety and efficacy for these common therapy allergens. Due to the long transitional provisions, the last deadlines for solving clinical shortcomings will end in 2026. The advantage of this regulation is that the market for common allergens has been cleared of products without proof of efficacy, and new preparations with an optimal dose range are developed through dose-finding studies. The demand for long-term pediatric studies has been outlined by the standard Pediatric Investigation Plan (PIP) on allergen products from the Pediatric Committee of the EMA (PDCO). This is particularly problematic, as it is foreseeable that recruitment of patients will be limited and ethical problems arise from the prolonged use of placebo. Furthermore, many newly approved preparations will not be used in pediatrics for the foreseeable future, as no marketing authorization has yet been granted for this age group. This will result in a serious supply gap for children.","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"7 ","pages":"236-241"},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10740145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139033146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allergen-specific immunotherapy and evidence: A European regulatory perspective. 过敏原特异性免疫疗法与证据：欧洲监管视角。

Allergologie select Pub Date : 2023-12-12 eCollection Date: 2023-01-01 DOI: 10.5414/ALX02413E

Detlef Bartel, Andreas Bonertz, Diana Hartenstein, Stefan Kaul, Iris Lauer, Christina Reeb, Karen Rösner-Friese, Katja Sliva, Julia Zimmer, Stefan Vieths, Vera Mahler

{"title":"Allergen-specific immunotherapy and evidence: A European regulatory perspective.","authors":"Detlef Bartel, Andreas Bonertz, Diana Hartenstein, Stefan Kaul, Iris Lauer, Christina Reeb, Karen Rösner-Friese, Katja Sliva, Julia Zimmer, Stefan Vieths, Vera Mahler","doi":"10.5414/ALX02413E","DOIUrl":"https://doi.org/10.5414/ALX02413E","url":null,"abstract":"Allergen immunotherapy (AIT) has been performed for 112 years. In this article we summarize regulatory standards and challenges based on scientific evidence on AIT. Most crucial and timely aspects concerning AIT are addressed from the regulatory perspective of the authors as employees of a national competent authority in Europe: (1) product specificity; (2) clinical efficacy; (3) treatment for adults and children (needs for extrapolation); (4) allergen exposure chambers; (5) biomarkers; (6) standardization; (7) real-world evidence; (8) independent official batch release (benefit and challenges); (9) harmonization on the EU level. The Paul-Ehrlich-Institut (PEI), the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main in Germany, examines and evaluates the benefits and risks of AIT products within the course of clinical development, marketing authorization, and subsequently throughout their entire life cycle to ensure high-quality, safe, and effective AIT products.","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"7 ","pages":"198-210"},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10740147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139033148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AIT 2023: Current innovation and future outlook. AIT 2023：当前创新与未来展望。

Allergologie select Pub Date : 2023-12-12 eCollection Date: 2023-01-01 DOI: 10.5414/ALX02379E

Magdalena Zemelka-Wiacek, Marek Jutel

引用次数: 0

Allergen immunotherapy of insect venom allergy: Almost 100 years old, but steadily updated. 昆虫毒液过敏的过敏原免疫疗法：近百年历史，不断更新。

Allergologie select Pub Date : 2023-12-12 eCollection Date: 2023-01-01 DOI: 10.5414/ALX02420E

Wolfgang Pfützner

引用次数: 0

DGAKI and PEI in dialogue 2023: Diagnostics and allergen immunotherapy. DGAKI 与 PEI 对话 2023：诊断和过敏原免疫疗法。

Allergologie select Pub Date : 2023-12-12 eCollection Date: 2023-01-01 DOI: 10.5414/ALX02450E

Oliver Pfaar, Eckard Hamelmann, Christian Taube, Martin Wagenmann, Bettina Wedi, Thomas Werfel, Detlef Bartel, Andreas Bonertz, Diana Hartenstein, Susanne Kaul, Vera Mahler, Margitta Worm

引用次数: 0